Wiley-Blackwell, the STM and scholarly publishing business of John Wiley & Sons, Inc., US, and EMBO have announced that EMBO Molecular Medicine will, as of March 2012, join the Wiley Open Access publishing programme. Articles in the journal will be open access and free to view, download and share for non-commercial use.
Since its launch in 2009, EMBO Molecular Medicine has attracted high quality submissions and attained a first Impact Factor of 8.833, placing it 6th in the Medicine Research and Experimental ISI Category. With its emphasis on translational medicine, the studies published in EMBO Molecular Medicine are of interest to a wide spectrum of researchers, clinicians and the public. Converting to open access allows all readers to benefit from the research advances reported in the journal, aiding the dissemination of biomedical research and accelerating discovery.
EMBO Molecular Medicine was the recipient of the 2009 PROSE Award for Best Journal/ Science, Technology and Medicine. The journal is supported by professional editors Anneke Funk and Céline Carret and an eminent international panel of Senior Editors, Drs. Dario Alessi, Giulio Cossu, Uta Francke, Fred Gage, Matthias Hentze, Edison T. Liu, Philippe Sansonetti and Bart de Strooper.
EMBO Molecular Medicine will publish all future articles under an Attribution-NonCommercial 3.0 Unported (CC BY-NC 3.0) Creative Commons License, which permits use, distribution, reproduction and adaptation in any medium, provided the original work is properly cited and is not used for commercial purposes. A publication fee will be payable by authors or their funder on acceptance of their primary research articles.
